MiRNA 34a: a therapeutic target for castration-resistant prostate cancer

Marine J Chalanqui, Michelle O'Doherty, Nicholas J Dunne, Helen O McCarthy

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

INTRODUCTION: Development of a therapy for bone metastases is of paramount importance for castration-resistant prostate cancer (CRPC). The osteomimetic properties of CRPC confer a propensity to metastasize to osseous sites. Micro-ribonucleic acid (miRNA) is non-coding RNA that acts as a post-transcriptional regulator of multiple proteins and associated pathways. Therefore identification of miRNAs could reveal a valid third generation therapy for CRPC. 

Areas covered: miR34a has been found to play an integral role in the progression of prostate cancer, particularly in the regulation of metastatic genes involved in migration, intravasation, extravasation, bone attachment and bone homeostasis. The correlation between miR34a down-regulation and metastatic progression has generated substantial interest in this field. 

Expert opinion: Examination of the evidence reveals that miR34a is an ideal target for gene therapy for metastatic CRPC. We also conclude that future studies should focus on the effects of miR34a upregulation in CRPC with respect to migration, translocation to bone micro-environment and osteomimetic phenotype development. The success of miR34a as a therapeutic is reliant on the development of appropriate delivery systems and targeting to the bone micro-environment. In tandem with any therapeutic studies, biomarker serum levels should also be ascertained as an indicator of successful miR34a delivery.

Original languageEnglish
Pages (from-to)1075-1085
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume20
Issue number9
Early online date28 Mar 2016
DOIs
Publication statusEarly online date - 28 Mar 2016

Fingerprint

Castration
Prostatic Neoplasms
Bone
Bone and Bones
Therapeutics
Gene therapy
Untranslated RNA
Biomarkers
MicroRNAs
Expert Testimony
Genetic Therapy
Genes
RNA
Homeostasis
Up-Regulation
Down-Regulation
Neoplasm Metastasis
Phenotype
Serum
Proteins

Cite this

Chalanqui, Marine J ; O'Doherty, Michelle ; Dunne, Nicholas J ; McCarthy, Helen O. / MiRNA 34a: a therapeutic target for castration-resistant prostate cancer. In: Expert Opinion on Therapeutic Targets. 2016 ; Vol. 20, No. 9. pp. 1075-1085.
@article{85f874c26d4b4f30a263f5e49eff71d6,
title = "MiRNA 34a: a therapeutic target for castration-resistant prostate cancer",
abstract = "INTRODUCTION: Development of a therapy for bone metastases is of paramount importance for castration-resistant prostate cancer (CRPC). The osteomimetic properties of CRPC confer a propensity to metastasize to osseous sites. Micro-ribonucleic acid (miRNA) is non-coding RNA that acts as a post-transcriptional regulator of multiple proteins and associated pathways. Therefore identification of miRNAs could reveal a valid third generation therapy for CRPC. Areas covered: miR34a has been found to play an integral role in the progression of prostate cancer, particularly in the regulation of metastatic genes involved in migration, intravasation, extravasation, bone attachment and bone homeostasis. The correlation between miR34a down-regulation and metastatic progression has generated substantial interest in this field. Expert opinion: Examination of the evidence reveals that miR34a is an ideal target for gene therapy for metastatic CRPC. We also conclude that future studies should focus on the effects of miR34a upregulation in CRPC with respect to migration, translocation to bone micro-environment and osteomimetic phenotype development. The success of miR34a as a therapeutic is reliant on the development of appropriate delivery systems and targeting to the bone micro-environment. In tandem with any therapeutic studies, biomarker serum levels should also be ascertained as an indicator of successful miR34a delivery.",
author = "Chalanqui, {Marine J} and Michelle O'Doherty and Dunne, {Nicholas J} and McCarthy, {Helen O}",
year = "2016",
month = "3",
day = "28",
doi = "10.1517/14728222.2016.1162294",
language = "English",
volume = "20",
pages = "1075--1085",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

MiRNA 34a: a therapeutic target for castration-resistant prostate cancer. / Chalanqui, Marine J; O'Doherty, Michelle; Dunne, Nicholas J; McCarthy, Helen O.

In: Expert Opinion on Therapeutic Targets, Vol. 20, No. 9, 28.03.2016, p. 1075-1085.

Research output: Contribution to journalReview article

TY - JOUR

T1 - MiRNA 34a: a therapeutic target for castration-resistant prostate cancer

AU - Chalanqui, Marine J

AU - O'Doherty, Michelle

AU - Dunne, Nicholas J

AU - McCarthy, Helen O

PY - 2016/3/28

Y1 - 2016/3/28

N2 - INTRODUCTION: Development of a therapy for bone metastases is of paramount importance for castration-resistant prostate cancer (CRPC). The osteomimetic properties of CRPC confer a propensity to metastasize to osseous sites. Micro-ribonucleic acid (miRNA) is non-coding RNA that acts as a post-transcriptional regulator of multiple proteins and associated pathways. Therefore identification of miRNAs could reveal a valid third generation therapy for CRPC. Areas covered: miR34a has been found to play an integral role in the progression of prostate cancer, particularly in the regulation of metastatic genes involved in migration, intravasation, extravasation, bone attachment and bone homeostasis. The correlation between miR34a down-regulation and metastatic progression has generated substantial interest in this field. Expert opinion: Examination of the evidence reveals that miR34a is an ideal target for gene therapy for metastatic CRPC. We also conclude that future studies should focus on the effects of miR34a upregulation in CRPC with respect to migration, translocation to bone micro-environment and osteomimetic phenotype development. The success of miR34a as a therapeutic is reliant on the development of appropriate delivery systems and targeting to the bone micro-environment. In tandem with any therapeutic studies, biomarker serum levels should also be ascertained as an indicator of successful miR34a delivery.

AB - INTRODUCTION: Development of a therapy for bone metastases is of paramount importance for castration-resistant prostate cancer (CRPC). The osteomimetic properties of CRPC confer a propensity to metastasize to osseous sites. Micro-ribonucleic acid (miRNA) is non-coding RNA that acts as a post-transcriptional regulator of multiple proteins and associated pathways. Therefore identification of miRNAs could reveal a valid third generation therapy for CRPC. Areas covered: miR34a has been found to play an integral role in the progression of prostate cancer, particularly in the regulation of metastatic genes involved in migration, intravasation, extravasation, bone attachment and bone homeostasis. The correlation between miR34a down-regulation and metastatic progression has generated substantial interest in this field. Expert opinion: Examination of the evidence reveals that miR34a is an ideal target for gene therapy for metastatic CRPC. We also conclude that future studies should focus on the effects of miR34a upregulation in CRPC with respect to migration, translocation to bone micro-environment and osteomimetic phenotype development. The success of miR34a as a therapeutic is reliant on the development of appropriate delivery systems and targeting to the bone micro-environment. In tandem with any therapeutic studies, biomarker serum levels should also be ascertained as an indicator of successful miR34a delivery.

U2 - 10.1517/14728222.2016.1162294

DO - 10.1517/14728222.2016.1162294

M3 - Review article

C2 - 26942553

VL - 20

SP - 1075

EP - 1085

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -